Antibody collaboration deal for Scancell CEO Cliff Holloway tells Proactive London why its antibody collaboration deal is significant and details how it complements Scancell's existing antibody technology. He also explains what is unique about Scancell's antibody pipeline. Thursday 5 September 2019 08:47 Categories: AvidiMab Interviews Media Coverage News Year - 2019 Previous Post << >> Next Post